A Phase II Trial to Assess the Safety, Immunological Activity of TroVax Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs MVA 5T4 (Primary) ; Cisplatin; Pemetrexed
- Indications Mesothelioma
- Focus Adverse reactions; Therapeutic Use
- Acronyms SKOPOS
- 13 Nov 2015 Status changed from recruiting to completed, according to United Kingdom Clinical Research Network.
- 13 Nov 2015 Planned End Date changed from 31 Jul 2015 to 27 Aug 2015, according to United Kingdom Clinical Research Network.
- 09 Nov 2015 Data from this trial is expected to be published in a peer-reviewed journal in 2016, according to an Oxford BioMedica media release.